Upstaging by Vessel Invasion Improves the Pathology Staging System of Non-Small Cell Lung Cancer

Tsuchiya, Tomoshi; Hashizume, Satoshi; Akamine, Shinji; Muraoka, Masashi; Honda, Sumihisa; Tsuji, K.; Urabe, Shougo; Hayashi, Tomayoshi; Yamasaki, Naoya; Nagayasu, Takeshi

doi:10.1378/chest.06-1950

Cited by 42 publications

(44 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Survival analysis indicated that a low PS and lymphatic vessel and blood vessel invasion are associated with shorter RFS times. These results are consistent with previous results that tumors with vessel invasion have aggressive growth and metastatic potential, which induce a poor prognosis [28,35]. …”

Section: Discussionsupporting

confidence: 93%

Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer

Tsuchiya¹,

Arai²,

Matsumoto³

et al. 2015

Chemotherapy

Self Cite

View full text Add to dashboard Cite

Background: Postoperative 1-year administration of S-1, an oral derivative of 5-fluorouracil (5-FU), was shown to be feasible in lung cancer. The 5-year survival rates of postoperative patients treated with S-1 adjuvant chemotherapy and the prognostic impact of clinicopathological factors were examined. Methods: The data of 50 patients with curatively resected pathological stage IB to IIIA non-small cell lung cancer, who were treated with S-1 postoperatively, were analyzed. The prognostic impacts of 22 clinicopathological factors including expressions of the 5-FU pathway enzymes were evaluated. A single-nucleotide polymorphism (SNP), i.e. 538G>A (rs17822931), of ABCC11/MRP8, which encodes a 5-FU excretion enzyme that is known as an earwax type determinant, was also evaluated. Results: The 5-year overall and relapse-free survival rates were 72.5 and 67.5%, respectively. A performance status ≥1, lymphatic vessel invasion, blood vessel invasion, and the A/A type of SNP538, which is responsible for the dry earwax type, were significantly associated with shorter relapse-free survivals. In 34 patients who showed a relative performance of 70% or more for chemotherapy, multivariate survival analysis indicated significant hazard ratios only for the A/A type of SNP538 (p = 0.007). Conclusions: S-1 has sufficient power as adjuvant chemotherapy. However, its effect might be small in the dry earwax type patient group in an adjuvant setting.

show abstract

Section: Discussionsupporting

confidence: 93%

Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer

Tsuchiya¹,

Arai²,

Matsumoto³

et al. 2015

Chemotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…14,15 Vascular invasion was determined by the identification of intravascular tumor clots in the lumen of lymphatic or blood vessels, as described previously. 16 …”

Section: Tissue Preparation and Histopathological Evaluationmentioning

confidence: 99%

High Expression of Dihydropyrimidine Dehydrogenase in Lung Adenocarcinoma is Associated With Mutations in Epidermal Growth Factor Receptor: Implications for the Treatment of Non–Small-Cell Lung Cancer Using 5-Fluorouracil

Mochinaga

Tsuchiya

Nagasaki

et al. 2014

Clinical Lung Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Intratumoral vessel invasion (IVI) of lymphatic vessels (IVI-L) or blood vessels (IVI-V) is an important pathological factor for lung carcinoma, both because it predicts metastasis and it has been shown to be an independent determinant of a poor prognosis in non-small cell lung carcinoma, especially in the early stages [5][6][7]. In addition, adjuvant chemotherapy can be beneficial for patients with stage IA lung carcinoma with IVI [8].…”

Section: Introductionmentioning

confidence: 99%

18F-FDG uptake in primary lung cancer as a predictor of intratumoral vessel invasion

et al. 2011

View full text Add to dashboard Cite

show abstract

Upstaging by Vessel Invasion Improves the Pathology Staging System of Non-Small Cell Lung Cancer

Cited by 42 publications

References 29 publications

Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer

Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer

High Expression of Dihydropyrimidine Dehydrogenase in Lung Adenocarcinoma is Associated With Mutations in Epidermal Growth Factor Receptor: Implications for the Treatment of Non–Small-Cell Lung Cancer Using 5-Fluorouracil

18F-FDG uptake in primary lung cancer as a predictor of intratumoral vessel invasion

Contact Info

Product

Resources

About